Swedish Orphan Biovitrum AB (publ) (BIOVF)
OTCMKTS
· Delayed Price · Currency is USD
27.66
-0.96 (-3.35%)
At close: Dec 23, 2024
BIOVF Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 25,435 | 22,123 | 18,790 | 15,529 | 15,261 | 14,248 | Upgrade
|
| Revenue Growth (YoY) | 19.58% | 17.74% | 21.00% | 1.76% | 7.11% | 55.90% | Upgrade
|
| Cost of Revenue | 5,442 | 4,952 | 4,413 | 3,484 | 3,225 | 3,319 | Upgrade
|
| Gross Profit | 19,993 | 17,171 | 14,377 | 12,045 | 12,036 | 10,929 | Upgrade
|
| Selling, General & Admin | 10,725 | 9,773 | 7,637 | 6,294 | 5,981 | 4,807 | Upgrade
|
| Research & Development | 3,340 | 2,743 | 2,252 | 1,987 | 1,594 | 1,448 | Upgrade
|
| Other Operating Expenses | -132 | -9 | -32 | -30 | -2 | -23 | Upgrade
|
| Operating Expenses | 13,933 | 12,507 | 9,857 | 8,251 | 7,573 | 6,232 | Upgrade
|
| Operating Income | 6,060 | 4,664 | 4,520 | 3,794 | 4,463 | 4,697 | Upgrade
|
| Interest Expense | -1,366 | -1,111 | -458 | -419 | -454 | -241 | Upgrade
|
| Interest & Investment Income | 27 | 27 | 5 | - | 1 | 5 | Upgrade
|
| Currency Exchange Gain (Loss) | -91 | -91 | -44 | 18 | -157 | -38 | Upgrade
|
| Other Non Operating Income (Expenses) | -50 | -49 | -27 | -35 | -33 | -20 | Upgrade
|
| EBT Excluding Unusual Items | 4,580 | 3,440 | 3,996 | 3,358 | 3,820 | 4,403 | Upgrade
|
| Merger & Restructuring Charges | -122 | -34 | -363 | - | - | -128 | Upgrade
|
| Gain (Loss) on Sale of Assets | -1 | -1 | - | -56 | -2 | 34 | Upgrade
|
| Asset Writedown | -65 | -65 | - | -7 | - | -63 | Upgrade
|
| Other Unusual Items | -185 | -385 | -312 | - | 399 | - | Upgrade
|
| Pretax Income | 4,207 | 2,955 | 3,321 | 3,295 | 4,217 | 4,246 | Upgrade
|
| Income Tax Expense | 693 | 546 | 683 | 616 | 972 | 942 | Upgrade
|
| Net Income | 3,514 | 2,409 | 2,638 | 2,679 | 3,245 | 3,304 | Upgrade
|
| Net Income to Common | 3,514 | 2,409 | 2,638 | 2,679 | 3,245 | 3,304 | Upgrade
|
| Net Income Growth | 26.91% | -8.68% | -1.53% | -17.44% | -1.79% | 36.64% | Upgrade
|
| Shares Outstanding (Basic) | 344 | 323 | 296 | 295 | 295 | 293 | Upgrade
|
| Shares Outstanding (Diluted) | 348 | 326 | 298 | 297 | 298 | 295 | Upgrade
|
| Shares Change (YoY) | 11.98% | 9.22% | 0.56% | -0.28% | 1.06% | 8.84% | Upgrade
|
| EPS (Basic) | 10.21 | 7.47 | 8.92 | 9.08 | 11.01 | 11.29 | Upgrade
|
| EPS (Diluted) | 10.08 | 7.39 | 8.84 | 9.03 | 10.90 | 11.22 | Upgrade
|
| EPS Growth | 13.28% | -16.39% | -2.11% | -17.16% | -2.85% | 25.64% | Upgrade
|
| Free Cash Flow | 6,354 | 4,063 | 4,504 | 5,423 | 4,885 | 3,597 | Upgrade
|
| Free Cash Flow Per Share | 18.24 | 12.46 | 15.09 | 18.27 | 16.41 | 12.21 | Upgrade
|
| Gross Margin | 78.60% | 77.62% | 76.51% | 77.56% | 78.87% | 76.71% | Upgrade
|
| Operating Margin | 23.83% | 21.08% | 24.06% | 24.43% | 29.24% | 32.97% | Upgrade
|
| Profit Margin | 13.82% | 10.89% | 14.04% | 17.25% | 21.26% | 23.19% | Upgrade
|
| Free Cash Flow Margin | 24.98% | 18.37% | 23.97% | 34.92% | 32.01% | 25.25% | Upgrade
|
| EBITDA | 9,454 | 7,548 | 6,593 | 5,604 | 6,319 | 6,077 | Upgrade
|
| EBITDA Margin | 37.17% | 34.12% | 35.09% | 36.09% | 41.41% | 42.65% | Upgrade
|
| D&A For EBITDA | 3,394 | 2,884 | 2,073 | 1,810 | 1,856 | 1,380 | Upgrade
|
| EBIT | 6,060 | 4,664 | 4,520 | 3,794 | 4,463 | 4,697 | Upgrade
|
| EBIT Margin | 23.83% | 21.08% | 24.06% | 24.43% | 29.24% | 32.97% | Upgrade
|
| Effective Tax Rate | 16.47% | 18.48% | 20.57% | 18.69% | 23.05% | 22.19% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.